Introduction
A convergence of scientific advances has enabled the identification of
molecular targets specific to cancer cells, resulting in therapies with enhanced
selectivity, efficacy and reduced toxicity. Developers can rise to the clinical,
regulatory and economic challenges to commercialization by improving strategic
decision-making in progressing drugs through the developmental pipeline.
Scope of this report
- Review of key innovatives in development including apoptosis stimulators
and inhibitors of angiogenesis, signal transduction and histone
deacetylation
- Analysis of trial data and marketing factors, with sales forecasts for key
technologies in late-stage clinical development
- Cancer overview including epidemiology, unmet needs, disease segmentation
and how innovative therapies will shift existing treatment paradigms
- Clinical, regulatory and pharmacoeconomic challenges and strategies for
commercialization
Research and analysis highlights
The cytostatic nature of many molecular-targeted treatments means that
significant tumor regressions are only likely to be seen in the context of
combinatorial treatment approaches alongside 'classic' cytotoxic treatments and
alternate molecular-targeted treatments.
The financial impact of adopting novel molecular-targeted treatments may be
prohibitive to market uptake. Mitigating this, improved diagnostic and
predictive analysis will facilitate predictive targeting of treatments to
patient populations most likely to respond.
Datamonitor believes the angiogenesis and signal transduction inhibitor
classes will provide the greatest revenue potential, congruent with their
combined clinical and commercial appeal. The crowded and competitive signal
transduction class will result in a high degree of fragmentation and
cannibalization, limiting potential revenue generation.
Key reasons to read this report
- Identify the key molecular-targeted anticancer drugs in clinical
development
- Assess opportunities and risks for innovative molecular targeted
treatments within the oncology market
- Adopt knowledge from this report to drive strategic planning for the
development of future treatments directed against unprecedented molecular
targets
| 
View Cart
